Department of Nuclear Medicine, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka city, Saitama prefecture, Japan.
Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1318-27. doi: 10.1007/s00259-010-1400-x. Epub 2010 Mar 20.
The purpose of this prospective study was to evaluate the usefulness of (18)F-fluorodeoxyglucose (FDG) and (11)C-choline positron emission tomography (PET)/computed tomography (CT) for detecting recurrences of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy. Additionally, we surveyed the time period during which an effective negative predictive value could be maintained after the first follow-up PET/CT examination and estimated the optimal timing of a second PET/CT examination for detecting late recurrences.
Fifty-three subjects (36 men and 17 women; mean age: 59.4 +/- 11.5 years) with advanced head and neck squamous cell carcinoma were recruited. Post-treatment (18)F-FDG PET/CT and (11)C-choline examinations were performed in all patients between 8 and 12 weeks after combined intra-arterial chemotherapy and radiotherapy. The PET/CT images were evaluated using a patient-based analysis and a lesion-based analysis. All of the patients were prospectively followed for at least 9 months after the post-treatment PET/CT examination, with surveillance using conventional images (including CT and/or MRI) and a physical examination performed every 3 months.
Recurrences, as determined using the patient-based analysis, were eventually confirmed in 18, 6 and 5 patients at 3, 4-6 and 7-9 months after the post-treatment PET/CT examination, respectively. The sensitivity and specificity of the 18F-FDG PET/CT and the 11C-choline PET/CT examinations to predict recurrence within 3 months were higher (FDG: 89 and 91%; choline: 83 and 80%, respectively) than for recurrence detection 6 months (FDG: 67 and 90%; choline: 62 and 76%, respectively) and 9 months later (FDG: 59 and 92%; choline: 55 and 75%, respectively). The lesion-based analysis showed that the maximum standardized uptake value of (18)F-FDG and (11)C-choline in the recurrent lesions were correlated with each other, compared with their relation in scar tissues (R (2) = 0.492 and 0.197, respectively).
(11)C-choline was not superior to (18)F-FDG for the detection of recurrent head and neck cancer. Both modalities had difficulty identifying recurrences at 4-9 months after the post-treatment PET/CT examination. In patients with advanced head and neck cancer who have received combined therapy, a second post-treatment PET/CT examination to check for late recurrences should be performed within 4-6 months after the first post-treatment PET/CT examination.
本前瞻性研究旨在评估(18)F-氟脱氧葡萄糖(FDG)和(11)C-胆碱正电子发射断层扫描(PET)/计算机断层扫描(CT)在头颈部癌联合动脉内化疗和放疗后检测复发的作用。此外,我们调查了首次随访 PET/CT 检查后可以维持有效阴性预测值的时间段,并估计了检测晚期复发的第二次 PET/CT 检查的最佳时间。
53 名(36 名男性和 17 名女性;平均年龄:59.4 ± 11.5 岁)晚期头颈部鳞状细胞癌患者被纳入研究。所有患者在联合动脉内化疗和放疗后 8-12 周进行治疗后(18)F-FDG PET/CT 和(11)C-胆碱检查。使用基于患者的分析和基于病变的分析对 PET/CT 图像进行评估。所有患者均在治疗后 PET/CT 检查后至少 9 个月内进行前瞻性随访,每 3 个月进行一次常规影像学(包括 CT 和/或 MRI)和体格检查。
基于患者的分析确定,在治疗后 PET/CT 检查后 3、4-6 和 7-9 个月,分别有 18、6 和 5 名患者最终确诊复发。(18)F-FDG PET/CT 和(11)C-胆碱 PET/CT 检查预测 3 个月内复发的敏感性和特异性更高(FDG:89%和 91%;胆碱:83%和 80%),而预测 6 个月(FDG:67%和 90%;胆碱:62%和 76%)和 9 个月(FDG:59%和 92%;胆碱:55%和 75%)后的复发较低。基于病变的分析表明,与瘢痕组织相比,复发病变中(18)F-FDG 和(11)C-胆碱的最大标准化摄取值相互相关(R(2)=0.492 和 0.197)。
(11)C-胆碱在检测头颈部癌复发方面并不优于(18)F-FDG。两种方法都难以在治疗后 PET/CT 检查后 4-9 个月识别复发。对于接受联合治疗的晚期头颈部癌患者,应在首次治疗后 PET/CT 检查后 4-6 个月内进行第二次治疗后 PET/CT 检查以检查晚期复发。